This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

​​​​​​​Who is the CRESEMBA® patient?

CRESEMBA may be an appropriate treatment option for a range of different patients. These could include patients in need of oral therapy, those at risk of particular drug-drug interactions associated with other azoles or those with renal impairment.​​​​​​​

Patient case studies illustrating use of CRESEMBA (isavuconazole) in a clinical setting

Lisa Nwankwo - Specialist Pharmacist, Antimicrobials

Patient case study illustrating use of isavuconazole in a clinical setting: A case of pulmonary mucormycosis

Card CTA

** This is an optional area where footnotes can live.

Lisa Nwankwo - Specialist Pharmacist, Antimicrobials

Patient case study illustrating use of isavuconazole in a clinical setting: Invasive aspergillosis in cystic fibrosis

Card CTA

** This is an optional area where footnotes can live.

Lisa Nwankwo - Specialist Pharmacist, Antimicrobials

Patient case study illustrating use of isavuconazole in a clinical setting:  A complex ITU patient

Card CTA

** This is an optional area where footnotes can live.

Arunaloke Chakrabarti - President of Interntional Society of Human & Animal Mycology

Covid-19 Associated Mucormycosis: An Emerging At-Risk Patient Population

Card CTA

** This is an optional area where footnotes can live.

Nelun Perera, Consultant Microbiologist

Sharing clinical experience of CRESEMBA (isavuconazole) in the UK

Footnotes

AML acute myeloid leukaemia, HIV human immunodeficiency virus, CLL chronic lymphocytic leukaemia

Explore more

Invasive Aspergillosis

An overview of the SECURE trial for CRESEMBA (isavuconazole).

Learn more

Mucormycosis

An overview of the VITAL trial for CRESEMBA (isavuconazole).

Learn more




​​​​​​​​​​​Prescribing Information

Cresemba (isavuconazole)
Great Britain

Cresemba (isavuconazole) 100mg hard capsules
Cresemba (isavuconazole) 200mg powder for concentrate for solution for infusion 

Northern Ireland
Cresemba (Isavuconazole) 100mg hard capsules and Cresemba (Isavuconazole) 200mg powder for concentrate for solution for infusion

Vfend (voriconazole)
Great Britain
​​​​​​​Vfend (voriconazole) 50mg film coated tablets
Vfend (voriconazole) 200mg film coated tablets
Vfend (voriconazole) 200mg powder for solution for infusion
Vfend (voriconazole) 40mg/ml powder for oral suspension

Northern Ireland
​​​​​​​
Vfend (voriconazole): 50mg film coated tablets, 200mg film coated tablets & 40mg/ml powder for oral suspension 

Meronem (meropenem trihydrate)
Great Britain

Meronem (meropenem trihydrate)IV 1g
Meronem (meropenem trihydrate) IV 500mg
Northern Ireland
Meronem (meropenem trihydrate)IV 1g
Meronem (meropenem trihydrate) IV 500mg

Diflucan (fluconazole)
Great Britain

Diflucan (fluconazole) Prescribing Information - 10mg/ml powder for oral suspension
Diflucan (fluconazole) Prescribing Information - 150mg capsules
Diflucan (fluconazole) Prescribing Information -  200mg hard capsules
Diflucan (fluconazole) Prescribing Information -  40mg/ml powder for oral suspension
Diflucan (fluconazole) Prescribing Information -  50mg hard capsules

Northern Ireland
Diflucan (fluconazole) Prescribing Information - 10mg/ml powder for oral suspension
Diflucan (fluconazole) Prescribing Information - 150mg capsules
Diflucan (fluconazole) Prescribing Information -  200mg hard capsules
Diflucan (fluconazole) Prescribing Information -  40mg/ml powder for oral suspension
Diflucan (fluconazole) Prescribing Information -  50mg hard capsules

​​​​​​​
​​​​​​​  PP-CRB-GBR-1429  February 2022

Antifungal Stewardship

Support for your Programme

Training

 Find out more

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?